Myovant Sciences Non Operating Income

Myovant Sciences Non Operating Income Calculation

Non-Recurring Items are the incomes received or expenses incurred by the business that are not from regular operations. Examples of NRI include gains (losses) from plant shutdown, lease-breaking fees, lawsuit, write-offs, write-downs, restructuring costs or sales of an investment, discontinued operations etc.

NRI can impact a company's reported income drastically.

Non Operating Income for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GuruFocus lists a PE Ratio without NRI, which is the price/earnings before NRI. We believe it more accurately reflects the valuation of the company.

Myovant Sciences's PE Ratio without NRI Ratio for today is calculated as

Myovant Sciences's Share Price of today is $10.84.
Myovant Sciences's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.21.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Myovant Sciences Non Operating Income Related Terms

Thank you for viewing the detailed overview of Myovant Sciences's Non Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Myovant Sciences Business Description

Industry

Healthcare » Biotechnology NAICS : 541714 SIC : 2834

Comparable Companies

NAS:AXSM NAS:IMAB NAS:RVNC NAS:BBIO NAS:RXRX NAS:CRNX NAS:VTYX NAS:LYEL NAS:GRNA NAS:ARQT OCSE:NOVO B ASX:CSL NAS:REGN NAS:VRTX NAS:MRNA XKRX:207940 NAS:BNTX HKSE:02269 NAS:SGEN SZSE:300122

Traded in Other Exchanges

71M:Germany

Address

11-12 St. James’s Square, Suite 1, 3rd Floor, London, GBR, SW1Y 4LB

Website

https://www.myovant.com

Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.

Executives

Potter Myrtle S	director	10 FINDERNE AVE BRIDGEWATER NJ 08807
Guinan Mark	director	C/O QUEST DIAGNOSTICS 500 PLAZA DRIVE SECAUCUS NJ 07094
Arjona Ferreira Juan Camilo	officer: Chief Medical Officer	C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005
Curran Terrie	director	C/O MYOVANT SCIENCES INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018
Gulfo Adele M.	director	ONE NEENAH CENTER, 4TH FLOOR P.O. BOX 669 NEENAH WI 54957
Sebelius Kathleen	director	C/O DERMIRA, INC. 275 MIDDLEFIELD ROAD, SUITE 150 MENLO PARK CA 94025
Lang Matthew	officer: General Counsel & Corp. Secy.	C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005
Sumitomo Chemical Co., Ltd.	10 percent owner	27-1, SHINKAWA 2-CHOME CHUO-KU TOKYO M0 104-8260
Sumitovant Biopharma Ltd.	10 percent owner	C/O ROIVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018
Dainippon Sumitomo Pharma Co Ltd	10 percent owner	60 WALL STREET NEW YORK NY 10005
Seely Lynn	director, officer: Principal Executive Officer	501 2ND STREET SUITE 211 SAN FRANCISCO CA 94107
Sablich Kim	officer: Chief Commercial Officer	C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005
Nomura Hiroshi	director	C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005
Roivant Sciences Ltd.	10 percent owner	CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Torti Frank	director	2855 SAND HILL ROAD MENLO PARK CA 94025